Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Condition:   Urinary Bladder Cancer, Muscle-invasive Interventions:   Drug: Pembrolizumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]);   Drug: Placebo Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials